Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, 14 people with ovarian, fallopian tube, or peritoneal cancer took part in this trial, and 12 of them completed it. The trial was testing whether infused donated immune cells called Natural Killer (NK) cells would multiply and grow inside the patients' bodies after being given, and it also tracked how patients' tumours responded and how long patients lived after treatment. Patients were split into two groups depending on whether they received a low-dose whole-body radiation treatment (called Total Body Irradiation, or TBI) beforehand or not. The reported data shows that for the primary goal — detecting whether the donated NK cells multiplied to a meaningful level in the body — the result was zero out of the patients assessed; the cells did not reach the target level in any participant. For tumour response, the reported data shows that across both groups, no patients had their tumours disappear completely and none had a meaningful shrinkage (called a partial response). In the no-TBI group, 4 patients had stable disease (tumours neither grew nor shrank enough to count as a change), and 1 had progressive disease (tumours grew). In the TBI group, 4 patients had stable disease and none had progressive disease. The data was not reported separately for the remaining response categories in a way that accounts for all 14 participants, so some individual figures may be missing from the submitted data. The reported data shows that the middle value (median) number of days before the disease progressed was 107 days for the no-TBI group and 90 days for the TBI group. For overall survival, the median number of days patients were alive after treatment was reported as 291 days in the no-TBI group and 171.5 days in the TBI group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back after previous treatment
- Your cancer can be measured on a scan, with at least one tumor spot measuring 1 cm or larger (cancer that has only spread to bones does not qualify)
- Your cancer has continued to grow or has not responded to at least 2 different chemotherapy treatments given after your cancer came back
- If you have had cancer spread to the brain in the past, it must have been stable for at least 3 months after treatment
- You have a related family member (such as a parent or sibling) who is a partial tissue-type match and could donate natural killer (NK) cells
- You are 18 years of age or older
- You are generally well enough to carry out normal daily activities with little or no limitation (as measured by a standard medical scale called GOG performance status 0 or 1)
- Your blood counts, kidney, liver, heart, and lung function are all within acceptable ranges, as confirmed by tests done within 14 days of joining the study
- You are able to stop taking prednisone or other immune-suppressing medicines for at least 3 days before the treatment starts
- You are willing and able to sign a consent form before any study-related procedures begin
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You are currently pregnant or breastfeeding, as the medicines used in this study could be harmful to a baby (a pregnancy test within 14 days of registering is required for anyone who could become pregnant)
- You currently have an active infection — you must have no fever, be off antibiotics, and have no unexplained suspicious areas showing on scans
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product
Other options
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.